End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.08 CNY | +0.57% | -0.42% | -11.50% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.50% | 6.42B | C- | ||
-1.62% | 90.85B | A- | ||
-0.92% | 39.02B | A- | ||
-10.72% | 33.46B | B- | ||
-19.66% | 14.51B | C | ||
-5.92% | 13.22B | B- | ||
-11.42% | 11.65B | D+ | ||
-47.31% | 10.57B | B | ||
+6.52% | 9.23B | B+ | ||
+137.06% | 7.71B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002252 Stock
- Ratings Shanghai RAAS Blood Products Co., Ltd.